JP2013514281A - エポシロン化合物並びにその調製方法及び用途 - Google Patents
エポシロン化合物並びにその調製方法及び用途 Download PDFInfo
- Publication number
- JP2013514281A JP2013514281A JP2012543447A JP2012543447A JP2013514281A JP 2013514281 A JP2013514281 A JP 2013514281A JP 2012543447 A JP2012543447 A JP 2012543447A JP 2012543447 A JP2012543447 A JP 2012543447A JP 2013514281 A JP2013514281 A JP 2013514281A
- Authority
- JP
- Japan
- Prior art keywords
- epothilone
- group
- compound
- enantiomer
- racemate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 51
- 150000001875 compounds Chemical class 0.000 title claims description 82
- 229930013356 epothilone Natural products 0.000 claims abstract description 53
- -1 epothilone compound Chemical class 0.000 claims abstract description 39
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 21
- 150000003883 epothilone derivatives Chemical class 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 230000002062 proliferating effect Effects 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 claims description 30
- XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 claims description 30
- XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 23
- 230000003287 optical effect Effects 0.000 claims description 22
- 125000006239 protecting group Chemical group 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 230000015572 biosynthetic process Effects 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 208000012868 Overgrowth Diseases 0.000 claims description 9
- 125000003277 amino group Chemical group 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 229930195735 unsaturated hydrocarbon Chemical group 0.000 claims description 8
- 230000010261 cell growth Effects 0.000 claims description 7
- 239000000969 carrier Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 150000003887 epothilone D derivatives Chemical class 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 238000006735 epoxidation reaction Methods 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
- 125000003700 epoxy group Chemical group 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 208000037803 restenosis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 230000036983 biotransformation Effects 0.000 claims description 2
- 230000000640 hydroxylating effect Effects 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims 1
- 239000008186 active pharmaceutical agent Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 abstract description 5
- 239000002994 raw material Substances 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 21
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 150000002430 hydrocarbons Chemical group 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- MQLACMBJVPINKE-UHFFFAOYSA-N 10-[(3-hydroxy-4-methoxyphenyl)methylidene]anthracen-9-one Chemical compound C1=C(O)C(OC)=CC=C1C=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MQLACMBJVPINKE-UHFFFAOYSA-N 0.000 description 6
- IOOMXAQUNPWDLL-UHFFFAOYSA-N 2-[6-(diethylamino)-3-(diethyliminiumyl)-3h-xanthen-9-yl]-5-sulfobenzene-1-sulfonate Chemical compound C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(S(O)(=O)=O)C=C1S([O-])(=O)=O IOOMXAQUNPWDLL-UHFFFAOYSA-N 0.000 description 6
- 0 CCCC[C@@](CC[C@@]1[C@](C)[C@](CCCC***=C[C@](*C)C(CC2)[C@@]2C2CCCCC2)CCC1)C1CC1 Chemical compound CCCC[C@@](CC[C@@]1[C@](C)[C@](CCCC***=C[C@](*C)C(CC2)[C@@]2C2CCCCC2)CCC1)C1CC1 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 229910004298 SiO 2 Inorganic materials 0.000 description 5
- 102000004243 Tubulin Human genes 0.000 description 5
- 108090000704 Tubulin Proteins 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 102000029749 Microtubule Human genes 0.000 description 4
- 108091022875 Microtubule Proteins 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 230000001851 biosynthetic effect Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 210000004688 microtubule Anatomy 0.000 description 4
- 229960001592 paclitaxel Drugs 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004593 Epoxy Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001540 azides Chemical class 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 150000003884 epothilone A derivatives Chemical class 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 150000003951 lactams Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003797 solvolysis reaction Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000016397 Methyltransferase Human genes 0.000 description 2
- 108060004795 Methyltransferase Proteins 0.000 description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 2
- 101150053185 P450 gene Proteins 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 241000862997 Sorangium cellulosum Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000003070 absorption delaying agent Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000005257 alkyl acyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000036815 beta tubulin Diseases 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- FFHWGQQFANVOHV-UHFFFAOYSA-N dimethyldioxirane Chemical compound CC1(C)OO1 FFHWGQQFANVOHV-UHFFFAOYSA-N 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 2
- 229960002014 ixabepilone Drugs 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000036457 multidrug resistance Effects 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000006303 photolysis reaction Methods 0.000 description 2
- 230000015843 photosynthesis, light reaction Effects 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 244000000000 soil microbiome Species 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- YWWDBCBWQNCYNR-UHFFFAOYSA-N trimethylphosphine Chemical compound CP(C)C YWWDBCBWQNCYNR-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- XNMQEEKYCVKGBD-UHFFFAOYSA-N 2-butyne Chemical group CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- JBLJNPFQUHRDRW-AJGWWKNYSA-N CC(CCC/C(/C)=C\C(C(/C(/C)=C/c1c[s]c(C)n1)OC(CC(C(C)(C)C(C1C)=O)O)=O)O)C1N=O Chemical compound CC(CCC/C(/C)=C\C(C(/C(/C)=C/c1c[s]c(C)n1)OC(CC(C(C)(C)C(C1C)=O)O)=O)O)C1N=O JBLJNPFQUHRDRW-AJGWWKNYSA-N 0.000 description 1
- ARCAJLRTCFFWQA-UHFFFAOYSA-N CN(C1=CC=CC2=CC=CC(=C12)N(C)C)C.C1(=CC=CC2=CC=CC(=C12)N)N Chemical compound CN(C1=CC=CC2=CC=CC(=C12)N(C)C)C.C1(=CC=CC2=CC=CC(=C12)N)N ARCAJLRTCFFWQA-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- WQZGKKKJIJFFOK-ZZWDRFIYSA-N L-glucose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-ZZWDRFIYSA-N 0.000 description 1
- RQVLGLPAZTUBKX-VKHMYHEASA-N L-vinylglycine Chemical compound C=C[C@H](N)C(O)=O RQVLGLPAZTUBKX-VKHMYHEASA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000005103 alkyl silyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- LLCSWKVOHICRDD-UHFFFAOYSA-N buta-1,3-diyne Chemical group C#CC#C LLCSWKVOHICRDD-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012084 conversion product Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000011981 lindlar catalyst Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000000585 macrolide polyketide group Chemical group 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- POPACFLNWGUDSR-UHFFFAOYSA-N methoxy(trimethyl)silane Chemical compound CO[Si](C)(C)C POPACFLNWGUDSR-UHFFFAOYSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- CPGRMGOILBSUQC-UHFFFAOYSA-N phosphoryl azide Chemical compound [N-]=[N+]=NP(=O)(N=[N+]=[N-])N=[N+]=[N-] CPGRMGOILBSUQC-UHFFFAOYSA-N 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
現在、より有効な化学療法剤としてのエポシロン及びその関連構造の類似体の開発が活発に行なわれている。例えば、化学半合成により、天然に存在するエポシロン化合物に対して修飾すること、また、PCT国際公開公報であるWO99/27890には、エポシロンBを相応するラクタム類似体であるBMS247550に転換する転換反応が記載されている。
本発明のその他の1つの実施形態において、本発明は、上記エポシロン化合物又はその薬学的に許容しうる塩、水和物、多結晶構造体、光学異性体、ラセミ体、非鏡像異性体又は鏡像異性体の、細胞の過成長を抑制する、または細胞成長を中止する医薬品の調製における応用を提供する。
本発明の一連の新規エポシロン化合物は、以下の一般式(I)のように示される。
Wは、NR1R又はO−Rであり、その中に、
Rは、H、ヒドロキシ又はアミノ基保護基、置換若しくは未置換の低級アルキル基又は不飽和炭化水素基から選ばれるものであり;好ましくは、H、アミノ基保護基、置換若しくは未置換のC1−6アルキル基又はC2−6アルケニル基から選ばれるものであり、更に好ましくは、CH3又はCF3である;
R1は、H、OH、置換若しくは未置換の低級アルキル基又は不飽和炭化水素基から選ばれるものであり、又はRと一緒にシクロアルキル(好ましくは、置換若しくは未置換のC1−6アルキル基又はC2−6アルケニル基から選ばれるものであり、又はRと一緒にC3−6シクロアルキルを形成する)を形成する;
その中に、前記Wは、更に好ましくは、NH2、O−CH3、 NHCH3、N(CH3)2又は
R2は、H、置換若しくは未置換の低級アルキル基又は不飽和炭化水素基から選ばれるものであり、又はC−4のその他の1つのメチル基と一緒に低級シクロアルキルを形成する;その中に、R2は、好ましくはH又はメチル基である;
R3は、H、OH又はNH2から選ばれるものである;
R4はH、置換若しくは未置換の低級アルキル基から選択しており、R4は、好ましくはCH3又はCF3である;
但し、一般式(I)において、14−OHエポシロンD及び4−デメチル基14−OHエポシロンDを含まない。
合成経路1:
合成経路2:
合成経路3:
脱保護をさせ、NHR1−の化合物を得ることができる。
合成経路4:
一般式(I)化合物の更に好ましい化合物は、エポキシ化物(12、13−エポキシ誘導体)である。当該種類化合物は、化学反応合成経路7に記載の通用方法をにより調製することができる。
合成経路7:
実施例1 14−ヒドロキシ化エポシロンD誘導体を調製する生物転換方法
1つのバイアル(1ml)凍結保存用チューブのStreptomyce sp. ATCC55098菌株を、5mlのシード培地(20g/L‐グルコース、20g/L‐ペプトン、10g/L酵母エキス(Yeast Extract);NaOHでpH7.0に調節;滅菌消毒した後で使用)に植菌した。培養物は、30℃振とう機にて2日培養した。培養物2.5mlをフラスコ内の発酵培地(発酵培地配合:パン酵母 30g/L、トウモロコシペースト15g/L、CaCO3 1g/L、コーンスターチ45g/L、HEPES 23.8g/L、デキストリン20g/L;NaOHでpH7.0に調節;滅菌消毒した後で使用)50mlに移し、その後、30℃で、24時間培養し、エポシロンD又は4−デメチル基エポシロンD等の誘導体5−10mgを培養液に添加し、引き続き2日〜3日培養した。培養物から転換生成物を単離し、同時に14−ヒドロキシル化エポシロン誘導体を回収した。
14−ヒドロキシエポシロンD(C27H42NO6S)のMS(ESI+):508.26[M+H]+
当該化合物の1H−NMRスペクトル及び13C−NMRスペクトルは図1及び図2をご参照する。
14−ヒドロキシ−21−ヒドロキシエポシロンD(C27H41NO7S)のMS(ESI+):524.26[M+H]+
14−NH2エポシロンD化合物II−A(C27H42N2O5S)のMS(ESI+):507.3[M+H]+
−78℃で、ジメチルジオキシラン溶液(アセトン中0.1M、17ml)を、本発明の脱酸素化合物(505mg)のCH2Cl2溶液10mlに滴下・加入した。混合物を−50℃まで加熱し、1時間保持してから、他の一部のジメチルジオキシラン溶液(5ml)を添加し、反応を−50℃の下で1.5時間継続させた。−50℃のN2ガス雰囲気中で反応物を乾燥させた。SiO2クロマトグラフィーで生成物を精製した。
14−NH2エポシロンB化合物II−B(C27H42N2O6S)のMS(ESI+):523.3[M+H]+
このような通用方法は、本発明のその他の化合物から相応的な12、13−エポキシ誘導体、例えば14−N(CH3)2エポシロンB化合物II−Lを調製することにも適用できる。
14−O−メチル基エポシロンD化合物II−M(C28H43NO6S)のMS(ESI+):522.3[M+H]+
生物活性的測定
スルホローダミンB(SRB)試験にて、本発明の選択的化合物の4種の異なる腫瘍細胞品系に対する抗癌活性をスクリーニングした。SRBの解析において、培養した細胞をトリプシン化させ、その後、計数し、そして成長培地で、好適な濃度(5000−7500細胞/100μl)に希釈した。100μl/穴の細胞懸濁液を96−穴のマイクロタイタープレートに添加し、細胞を植菌した。20時間後、成長培地において2x1000nM〜2x0.001nMに希釈されたテスト用化合物100μlを各穴に添加した。3日間の培養を行った後、10%のトリクロロ酢酸100μlを使用して、4℃の下で細胞を1時間固定し、その後、0.2%SRB/1%酢酸を用いて室温下で20分間染色した。1%の酢酸にて、結合しなかった染料を洗い流し、10mMのTris塩基200μlで結合したSRBを溶解した。結合した染料の量は、波長515nmにおけるOD値を測定することにより推算した。結合した染料の量は、細胞タンパク質の総量と正比例をなす。データは、Kaleida Graphプログラムで解析し、そして半抑制濃度(IC50)を計算した。比較のために、エポシロンD及びBを平行テストした。本発明中の測定された選択性化合物の細胞毒性の試験結果を、以下の通り示す。本発明のその他の化合物に対しても、類似する方法により測定することができる。
チューブリン重合試験は、本発明のエポシロン誘導体がエポシロンと同じ作用メカニズムを有することを示しており、テストの条件下で、エポシロンと類似する動力学及び効用を有している。本発明のその他の化合物に対しても、同じ方法で測定することができる。
Claims (11)
- 以下の一般式(I)に示されるエポシロン化合物であることを特徴とする、エポシロン化合物又はその化合物の薬学的に許容しうる塩、水和物、多結晶構造体、光学異性体、ラセミ体、非鏡像異性体又は鏡像異性体。
WはNR1R又はO−Rであり、その中に、
RはH、ヒドロキシ又はアミノ基保護基、置換若しくは未置換の低級アルキル基又は不飽和炭化水素基から選ばれるものである;
R1はH、OH、置換若しくは未置換の低級アルキル基又は不飽和炭化水素基から選ばれるものであり、又はRと一緒にシクロアルキルを形成する;
R2はH、置換若しくは未置換の低級アルキル基又は不飽和炭化水素基から選ばれるものであり、又はC−4のその他の1つのメチル基と一緒に低級シクロアルキルを形成する;
R3はH、OH又はNH2から選ばれるものである;
R4はH、置換若しくは未置換の低級アルキル基から選ばれるものである;
且つ、14−OHエポシロンD及び4−デメチル基14−OHエポシロンDを含まない。 - WはNR1R又はO−Rであり、その中に、RはH、アミノ基保護基、置換若しくは未置換のC1−6アルキル基又はC2−6アルケニル基から選ばれるものであり、R1はH、置換若しくは未置換のC1−6アルキル基又はC2−6アルケニル基から選ばれるものであり、又はRと一緒にC3−6シクロアルキルを形成することを特徴とする、請求項1に記載のエポシロン化合物又はその化合物の薬学的に許容しうる塩、水和物、多結晶構造体、光学異性体、ラセミ体、非鏡像異性体又は鏡像異性体。
- 請求項1−4のいずれかに記載の化合物又はその化合物の薬学的に許容しうる塩、水和物、多結晶構造体、光学異性体、ラセミ体、非鏡像異性体又は鏡像異性体、及び1種又は多種の薬用担体及び/又は希釈剤を含むことを特徴とする、医薬組成物。
- 更に1種又は多種のその他の活性医薬品を含むことを特徴とする、請求項5に記載の組成物。
- 請求項1〜4のいずれかに記載の化合物又はその化合物の薬学的に許容しうる塩、水和物、多結晶構造体、光学異性体、ラセミ体、非鏡像異性体又は鏡像異性体の、増殖性疾患を治療する医薬品の調製における応用。
- 前記増殖性疾患は腫瘍、多発性硬化症、関節リウマチ、アテローム性動脈硬化症及び再狭窄から選ばれるものであることを特徴とする、請求項7に記載の応用。
- 請求項1〜4のいずれかに記載の化合物又はその化合物の薬学的に許容しうる塩、水和物、多結晶構造体、光学異性体、ラセミ体、非鏡像異性体又は鏡像異性体の、細胞の過成長を抑制する、及び細胞成長を中止する医薬品の調製における応用。
- 請求項1〜4のいずれかに記載の化合物又はその化合物の薬学的に許容しうる塩、水和物、多結晶構造体、光学異性体、ラセミ体、非鏡像異性体又は鏡像異性体を調製する方法であって、当該方法は以下のことから選ばれるものであることを特徴とする方法。
1)エポシロンD及びその誘導体から微生物の生物転換又は微生物由来のヒドロキシ化酵素であるP450酵素により、ヒドロキシ化エポシロンD誘導体を調製する;
2)14−ヒドロキシエポシロン誘導体から化学反応合成経路により、14−NRR1−エポシロン誘導体を調製する;又は
2’)14−ヒドロキシエポシロン誘導体から化学反応合成経路により、14−O−メチル基−エポシロン誘導体を調製する;
3)ステップ2’)における14−O−メチル基−エポシロン誘導体から化学反応合成経路により、14−O−メチル基−ラクタムエポシロン誘導体を調製する。 - 請求項1〜4のいずれかに記載の化合物又はその化合物の薬学的に許容しうる塩、水和物、多結晶構造体、光学異性体、ラセミ体、非鏡像異性体又は鏡像異性体を調製する方法であって、14−W−エポシロンD誘導体における炭素−炭素二重結合を化学エポキシ化反応によりA−Dがエポキシ基である化合物の14−W−エポシロンB誘導体を得ることを特徴とする方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910259234.7A CN102101863B (zh) | 2009-12-17 | 2009-12-17 | 新型环氧噻酮化合物及其制备方法和用途 |
CN200910259234.7 | 2009-12-17 | ||
PCT/CN2010/002078 WO2011072496A1 (zh) | 2009-12-17 | 2010-12-17 | 环氧噻酮化合物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013514281A true JP2013514281A (ja) | 2013-04-25 |
JP5839328B2 JP5839328B2 (ja) | 2016-01-06 |
Family
ID=44154952
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012543447A Active JP5839328B2 (ja) | 2009-12-17 | 2010-12-17 | エポシロン化合物並びにその調製方法及び用途 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8895590B2 (ja) |
EP (1) | EP2514752B1 (ja) |
JP (1) | JP5839328B2 (ja) |
CN (1) | CN102101863B (ja) |
WO (1) | WO2011072496A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023509871A (ja) * | 2020-04-08 | 2023-03-10 | 北京華昊中天生物医薬股▲ふん▼有限公司 | ウチデロン半水和物単結晶、並びにその調製方法及び応用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1521258A (zh) * | 2003-01-28 | 2004-08-18 | 北京华昊中天生物技术有限公司 | 一类新型埃坡霉素化合物及其制备方法和用途 |
WO2009105969A1 (zh) * | 2008-02-29 | 2009-09-03 | 唐莉 | 15环噻酮化合物及其制备方法与应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
EP1185301A1 (en) | 1999-05-24 | 2002-03-13 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
CN100387706C (zh) | 2003-08-15 | 2008-05-14 | 北京华昊中天生物技术有限公司 | 治疗肿瘤和血管再狭窄的微管稳定剂埃坡霉素 |
-
2009
- 2009-12-17 CN CN200910259234.7A patent/CN102101863B/zh active Active
-
2010
- 2010-12-17 EP EP10836935.6A patent/EP2514752B1/en active Active
- 2010-12-17 WO PCT/CN2010/002078 patent/WO2011072496A1/zh active Application Filing
- 2010-12-17 JP JP2012543447A patent/JP5839328B2/ja active Active
-
2012
- 2012-06-18 US US13/526,097 patent/US8895590B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1521258A (zh) * | 2003-01-28 | 2004-08-18 | 北京华昊中天生物技术有限公司 | 一类新型埃坡霉素化合物及其制备方法和用途 |
WO2009105969A1 (zh) * | 2008-02-29 | 2009-09-03 | 唐莉 | 15环噻酮化合物及其制备方法与应用 |
Non-Patent Citations (1)
Title |
---|
JPN6013064598; FREIN,J.D. et al: Organic Letters Vol.11, No.15, 2009, p.3186-3189 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2023509871A (ja) * | 2020-04-08 | 2023-03-10 | 北京華昊中天生物医薬股▲ふん▼有限公司 | ウチデロン半水和物単結晶、並びにその調製方法及び応用 |
Also Published As
Publication number | Publication date |
---|---|
US8895590B2 (en) | 2014-11-25 |
EP2514752A1 (en) | 2012-10-24 |
CN102101863A (zh) | 2011-06-22 |
US20120322838A1 (en) | 2012-12-20 |
JP5839328B2 (ja) | 2016-01-06 |
EP2514752A4 (en) | 2013-05-15 |
EP2514752B1 (en) | 2018-01-31 |
WO2011072496A1 (zh) | 2011-06-23 |
CN102101863B (zh) | 2014-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101173510B1 (ko) | 에포틸론, 이의 중간물질과 유사체의 합성 및 이들의 용도 | |
US6531497B1 (en) | Epothilone derivatives and their synthesis and use | |
US20050192440A1 (en) | Method for synthesizing epothilones and epothilone analogs | |
JP2011513248A (ja) | エポシロン類似体及びその医薬組成物、応用並びにその調製方法 | |
WO1999067253A2 (en) | Desmethyl epothilones | |
WO2005084222A2 (en) | Synthesis of epothilones, intermediates thereto, analogues and uses thereof | |
CA2425620A1 (en) | 13-alkyl epothilone derivatives | |
JP5839328B2 (ja) | エポシロン化合物並びにその調製方法及び用途 | |
US20040053995A1 (en) | Synthesis of epothilones, intermediates thereto and analogues thereof | |
US20040053910A1 (en) | Synthesis of epothilones, intermediates thereto and analogues thereof | |
RU2311415C2 (ru) | Синтез эпотилонов, их промежуточных продуктов, аналогов и их применения | |
Greiner | Total synthesis of de-aryl epothilone and synthesis of analogs | |
MXPA06009792A (en) | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140402 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141118 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150813 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150915 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151015 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20151023 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151030 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20151023 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5839328 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |